Yun Jee Seo
Overview
Explore the profile of Yun Jee Seo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
672
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nam Y, Koo H, Yang Y, Shin S, Zhu Z, Kim D, et al.
Genome Med
. 2023 Mar;
15(1):16.
PMID: 36915208
Background: Although temozolomide (TMZ) has been used as a standard adjuvant chemotherapeutic agent for primary glioblastoma (GBM), treating isocitrate dehydrogenase wild-type (IDH-wt) cases remains challenging due to intrinsic and acquired...
2.
Shin K, Shin H, Cho H, Kang H, Lee J, Seo Y, et al.
Cancers (Basel)
. 2020 Mar;
12(3).
PMID: 32120790
Diffusely infiltrating gliomas (DIGs) are difficult to completely resect and are associated with a high rate of tumor relapse and progression from low- to high-grade glioma. In particular, optimized short-term...
3.
Sa J, Hong J, Lee I, Kim J, Sim M, Kim H, et al.
Genome Med
. 2020 Feb;
12(1):17.
PMID: 32070411
Background: Gastric cancer is among the most lethal human malignancies. Previous studies have identified molecular aberrations that constitute dynamic biological networks and genomic complexities of gastric tumors. However, the clinical...
4.
Sa J, Hwang J, Cho Y, Ryu J, Choi J, Jeong S, et al.
Genome Biol
. 2019 Nov;
20(1):253.
PMID: 31771620
Background: Gynecologic malignancy is one of the leading causes of mortality in female adults worldwide. Comprehensive genomic analysis has revealed a list of molecular aberrations that are essential to tumorigenesis,...
5.
Shin H, Sa J, Bae J, Koo H, Jin S, Cho H, et al.
Cancer Res Treat
. 2019 May;
52(1):41-50.
PMID: 31096737
Purpose: Targeted next-generation sequencing (NGS) panels for solid tumors have been useful in clinical framework for accurate tumor diagnosis and identifying essential molecular aberrations. However, most cancer panels have been...
6.
Lee J, Liu Z, Sa J, Shin S, Wang J, Bordyuh M, et al.
Nat Genet
. 2018 Sep;
50(10):1399-1411.
PMID: 30262818
Outcomes of anticancer therapy vary dramatically among patients due to diverse genetic and molecular backgrounds, highlighting extensive intertumoral heterogeneity. The fundamental tenet of precision oncology defines molecular characterization of tumors...
7.
Cho H, Zhao J, Jung S, Ladewig E, Kong D, Suh Y, et al.
Neuro Oncol
. 2018 Aug;
21(1):47-58.
PMID: 30085274
Background: Despite extensive efforts on the genomic characterization of gliomas, very few studies have reported the genetic alterations of cerebellar glioblastoma (C-GBM), a rare and lethal disease. Here, we provide...
8.
Lee J, Wang J, Sa J, Ladewig E, Lee H, Lee I, et al.
Nat Genet
. 2017 Mar;
49(4):594-599.
PMID: 28263318
Precision medicine in cancer proposes that genomic characterization of tumors can inform personalized targeted therapies. However, this proposition is complicated by spatial and temporal heterogeneity. Here we study genomic and...
9.
Kim D, Kim K, Seo Y, Yang H, Marcusson E, Son E, et al.
Oncotarget
. 2016 Apr;
7(20):29400-11.
PMID: 27102443
Small non-coding RNAs called miRNAs are key regulators in various biological processes, including tumor initiation, propagation, and metastasis in glioblastoma as well as other cancers. Recent studies have shown the...
10.
Lee Y, Kim K, Kim D, Cho H, Kim Y, Rheey J, et al.
PLoS One
. 2015 Oct;
10(10):e0137703.
PMID: 26444992
Glioblastoma (GBM) is the most aggressive and most lethal brain tumor. As current standard therapy consisting of surgery and chemo-irradiation provides limited benefit for GBM patients, novel therapeutic options are...